Background: Genetic diversity of human immunodeficiency virus affects the treatment and the emergence of resistance. Some subtypes would develop resistance more frequently than others. The aim of this study is to determine the rate of virological treatment failure and the involvement of genetic diversity and different mutations in this failure in Kinshasa. Methods: Of the 153 Antiretroviral-naive patients who were included in the cohort, 138 patients have been received for the appointment of the 6 th month. Clinical parameters were
tions are involved in treatment failure.
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Backgrounds
The Human Immunodeficiency Virus (HIV) has a genetic diversity that is equal to the complexity of its management [1] . The classification of types, groups, subgroups, sub-groups and different recombinant forms (CRFs-Circulating Recombinant Forms) or mutant allowed better understanding the virus, its geographical distribution and the evolution of the epidemic [1] - [7] . It also helped direct the management of patients infected by HIV [1] - [7] . Group M (Major) is the dominant group in Central Africa [1] - [7] . The distribution of this group in Africa and the Democratic Republic of Congo (DRC), in particular, is very heterogeneous; it follows a complex and specific algorithm [1] - [7] . This distribution is very dynamic, progressive and unpredictable; it will continue to diversify as long as the virus circulates [1] - [7] . There is a very large genetic diversity of this group M in the DRC and particularly in Kinshasa [1] - [7] . The subtype B, which is the dominant one in Western Europe and North America has a prevalence <1% in Kinshasa [1] .
The genetic diversity of HIV affects the treatment and the emergence of resistant strains [8] . Some subtypes would develop resistance more frequently than subtypes A and B [9] ; this could cause some natural nucleotide polymorphisms on specific codons [10] [11].
Treatment failure includes a variety of situations, whether virological failure resulting from a persistent viral replication 6 months after starting treatment (Viral load > 200 RNA copies/ml or 2.30 log 10 RNA copies/ml), an immunological failure with persistent immunodeficiency (CD4 count < 200 cells/mm 3 ) or clinical failure that usually associated virological failure and immune deterioration [12] . In 2012, 16% of patients in the first line antiretroviral therapy (ART) were estimated in treatment failure in Kinshasa [13] .
The aim of this study is to determine the rate of virological treatment failure and the involvement of genetic diversity and different mutations in this failure in Kinshasa.
Methodology

Study Population
At baseline, 153 patients naïve to Antiretroviral Therapy (ART) were selected for follow-up with different support centers in Kinshasa. The inclusion criteria for subjects in the cohort were: (i) being diagnosed HIV-1 positive according to national guidelines [14] , (ii) being over the age of 18 years at the inclusion in the cohort, (iii) being eligible for ART in the monitoring center and (iv) be naive to ART. Viral Loads (VL), the different HIV-1 strains and the different mutations associated with resistance to ART were determined for all patients at baseline [15] [16] . The 6 th month of ART, only 138 patients (90.2%) of the cohort have been received on the 153 included in the first day.
Clinical and Biological Monitoring Parameters
Clinical parameters were collected on individual patient charts in their respective centers as well as the survey forms. The determination of the VL was done in the laboratory of Molecular Biology of the Faculty of Medicine University of Kinshasa (UNIKIN) using the same "in-house" assays used at the inclusion [16] [17] [18] [19] . The count of CD4+ lymphocytes was done by flow cytometry.
Comparison of Variables
In order to determine the evolution of patients under treatment, clinical and bi- VLs were determined using the same "in-house" assays under the same conditions. Correlation tests were done between profiles at baseline and those at the 6 th month, VLs at baseline and mortality, VLs at baseline and treatment failure, and the prevalence of acquired mutations and failures treatment.
Statistics
Pearson correlation test was used to analyze the data. The value of p < 0.06 is considered to accommodate the size of our sample.
Operational Definition
The virological failure is defined as a persistent VL higher than 200 RNA copies/ml (2.30 log 10 RNA copies/ml) 6 months after the start of treatment [20] .
Three definitions are presented for virological failure: the minimal failure (200 < VL < 5000 or 2.30 log 10 < VL < 3.70 log 10 RNA copies/ml), moderate failure (5000 < VL < 30 000 or 3.70 log 10 < VL < 4.48 log 10 RNA copies/ml) and severe failure (VL > 30 000 or VL > 4.48 log 10 RNA copies/ml) [20] [21] . The patients lost are those who did not return for their appointment the 6 th month and have not been found by the community relay service from the centers.
Results
Epidemiological Data
At the 6 th month follow-up, 138 patients (90.2%) had returned out of the 153 patients included at baseline. Eighty-one (58.7%) patients were women and 57 (41.3%) male (Table 1) ; with a sex ratio M/F of 0.70 (p < 0.06). The age of patients ranges between 18 and 65 years with an average of 37 years ( Table 1 ). The 
Clinical and Biological Data
At 6 th months, 5 patients were lost from the relays service (2 women and 3 men) and 10 patients were reported dead (8 women and 2 men) ( RNA copies/ml. The minimum and maximum values were respectively 0 and 4.82 log 10 RNA copies/ml with 104 patients (75.4%) with a VLunder 200 RNA copies/ml or 2.3 log 10 RNA copies/ml giving a rate of virological failure of 24.6%
( 
Resistance and Treatment Failure
In a previous study, the types of mutations and various associated prevalence were described for this population [15] . According to the Pearson's test, LVs at 
Discussion
This study aimed to determine the rate of virological treatment failure and the (67.7%) in moderate failure (3.70 log 10 < VL < 4.48 log 10 RNA copies/ml) and 3 (8.8%) in severe failure (VL > 4.48 log 10 RNA copies/ml). Most failed patients (67.7%) are moderate virological failure. In the past, virological failure was estimated at 14.6% in 2010 [25] and 16% in 2012 [13] for the city of Kinshasa, taking into account 3 clinics that were among the recommended centers for treatment at the time [24] . The difference in numbers is in the inclusion criteria of patients and selection centers, and the criteria for determining the processing failure. Indeed, the virological failure was redefined as a VL > 200 RNA copies/ml (2.3 log 10 RNA copies/ml) in 2013 [20] as opposed to a VL > 1000 copies of RNA copies/ml (3.0 log 10 RNA copies/ml) in previous years [21] . In this study, 2 centers that met the criteria according to WHO's recommendations were randomly selected by district of Kinshasa [24] . Eight treatment centers participated in this study. Hence for Kinshasa, according to the updated criteria, the rate of virological failure is estimated at 24.6% for 2014.
According to the Pearson's test, the VLs in the 6 th month were highly correlated with that of baseline (R 2 = 0.641, p < 0.000), with the K70 codon mutation for NRTI (R 2 = 0.558, p < 0.000), with the V75 for NRTI (R 2 = 0.448, p < 0.000),
with the V108 for NNRTI (R 2 = 0.413, p < 0.000), and with the virological treatment failure (R 2 = 0.947; p < 0.000). Various studies have shown that a high VL (CV > 5.00 log 10 ) before starting treatment is a badprognosis for treatment, where the patient is doomed to failure [26] [27] . Some studies have implicated the K103N and Y181C mutations for resistance and failure to treatment [28] [29]. But in our case, the mutated codons that are responsible for treatment failure are: K70, V75 for NRTI and V108 for NNRTI. This presents a profile of different resistance mutations to Kinshasa specific to the different variants; this corresponds to what has been published in Africa for non-B subtypes [30] .
On the other hand, some correlations in the emergence of codons mutations were noted such as K70 NRTI and V75 NRTI (R 2 = 0.512, p < 0.000), K70 NRTI and T215 NRTI (R 2 = 0.453, p < 0.000), V75 NRTI and Y115 NRTI (R 2 = 0.465, p < 0.000), V106 NNRTI and V108 NNRTI (R 2 = 0.595, p < 0.000) as well as Y115
NRTI and L100 NNRTI (R 2 = 0.593; p < 0.000).
Limitation of Study
Due to different constraints, the determination of mutations 6 th month after the beginning of treatment was not done. However, this does not remove the pertinence of the results. They related to the involvement of transmitted mutations in the treatment failure and responded to the prerogatives and actual questions on mutations.
Conclusion
Our results confirmed the hypothesis that high Viral Load at start of treatment is a poor prognosis for the therapeutic development of the patient. Correlations between virological failure, acquired mutations and viral load at baseline reinforce the importance of the usefulness of genotyping tests and viral load in early treatment to improve treatment and for adequate therapy.
